Venus Remedies Ltd

Venus Remedies has announced its financial results for the quarter ending December 2024, revealing significant year-on-year growth in Profit Before Tax and Profit After Tax. Net sales increased notably, and the operating profit margin reached a five-quarter high, indicating improved efficiency and profitability for the company.

Venus Remedies, a microcap in the Pharmaceuticals & Drugs sector, reached a new 52-week low today, continuing a five-day downward trend with a cumulative loss. Despite this, it outperformed its sector. The stock has struggled over the past year, significantly underperforming compared to the Sensex.

Venus Remedies, a microcap pharmaceutical company, has reported a negative financial performance in the second quarter of fiscal year 2024-2025. While cash and cash equivalents have improved, PBT and PAT have shown a decline. Operating profit and efficiency have also decreased, with high income from non-business activities. Investors should carefully consider these factors before investing.

Venus Remedies, a microcap pharmaceutical company, has been downgraded to 'Sell' by MarketsMOJO due to a bearish trend and deteriorating technical indicators. However, the company has a strong ability to service debt, healthy long-term growth, positive recent results, and attractive valuation. Majority of shareholders are non-institutional, indicating uncertainty in future prospects.

Venus Remedies, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO due to its strong ability to service debt and healthy long-term growth. In the past year, the company has declared positive results and has a strong cash position. With attractive valuation and potential undervaluation, it is a stock to watch in the pharmaceutical industry.

Venus Remedies, a microcap pharmaceutical company, was downgraded to 'Sell' by MarketsMOJO on October 11, 2024 due to a bearish trend and technical factors. However, the company has a strong ability to service debt, healthy long-term growth, positive financial results, and attractive valuation. Majority shareholders are non-institutional investors.

Venus Remedies, a microcap pharmaceutical company, has reported a positive financial performance for the quarter ending March 2024. With a score of 9 out of 10, the company's Profit Before Tax (PBT) and Net Sales have shown significant growth. The company's stock has been given a 'Hold' call by MarketsMOJO.

Venus Remedies, a microcap pharmaceutical company, has received an upgraded stock call from MarketsMOJO to 'Hold'. The decision is based on the company's strong ability to service debt, healthy long-term growth, positive results in the last three quarters, and bullish technical indicators. Despite low mutual fund interest, the company remains a promising player in the industry.

Venus Remedies has received a 'Sell' call from MarketsMOJO for the quarter ending Mar 2024, despite positive net sales growth. The company's PBT and PAT have declined, leading to a decrease in overall financial performance. However, net sales have increased by 25.39% year on year, while non-operating income has also risen. Investors should carefully consider these factors before making any investment decisions.

Venus Remedies, a microcap pharmaceutical company, has been downgraded to 'Sell' by MarketsMOJO due to a Mildly Bearish stock range and deteriorating technical trend. However, the company has a strong ability to service debt, healthy long-term growth rate, positive financial results, and fair valuation. Despite recent downgrade, the stock has outperformed the market and shows potential for long-term growth.

Venus Remedies, a microcap pharmaceutical company, has shown a significant improvement in its financial performance for the quarter ended September 2023. However, the company's increasing debt to equity ratio and falling operating cash flow are areas of concern. Investors are advised to monitor the company's performance closely.

Venus Remedies, a microcap pharmaceutical company, has received a 'Hold' rating from MarketsMOJO on November 6, 2023. This is due to its strong ability to service debt, healthy long-term growth rate, and impressive financials. The stock has also shown a significant improvement and outperformed the market in the last year. However, domestic mutual funds hold 0% of the company, possibly due to its current premium valuation.

Venus Remedies has further consolidated its position in the Gulf Cooperation Council (GCC), Association of South East Asian Nations (ASEAN), Balkan and Caribbean regions. The company has secured 503 marketing approvals for its oncology products across 75 countries. The market size of cancer drugs was valued at $417 million in 2019.

The stock hit a high of Rs 238.35 on the BSE, up 20 percent from its previous close. The benchmark Sensex edged up 0.2 percent to 62,973 points. Revenue for the quarter jumped 15.34 percent to Rs 148.53 crore last year.